JP2003513051A - Ｃ．ｄｉｆｆｉｃｉｌｅトキシンＢ関連性状態の処置 - Google Patents

Ｃ．ｄｉｆｆｉｃｉｌｅトキシンＢ関連性状態の処置

Info

Publication number
JP2003513051A
JP2003513051A JP2001534423A JP2001534423A JP2003513051A JP 2003513051 A JP2003513051 A JP 2003513051A JP 2001534423 A JP2001534423 A JP 2001534423A JP 2001534423 A JP2001534423 A JP 2001534423A JP 2003513051 A JP2003513051 A JP 2003513051A
Authority
JP
Japan
Prior art keywords
toxin
βglc
αglc
oligosaccharide sequence
linker arm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001534423A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003513051A5 (https=
Inventor
ルイス ディー． ヒアーズ，
グレン ディー． アームストロング，
Original Assignee
シンソーブ バイオテック， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シンソーブ バイオテック， インコーポレイテッド filed Critical シンソーブ バイオテック， インコーポレイテッド
Publication of JP2003513051A publication Critical patent/JP2003513051A/ja
Publication of JP2003513051A5 publication Critical patent/JP2003513051A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
JP2001534423A 1999-11-04 2000-11-03 Ｃ．ｄｉｆｆｉｃｉｌｅトキシンＢ関連性状態の処置 Pending JP2003513051A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/433,944 US6358930B1 (en) 1998-05-28 1999-11-04 Treatment of C. difficile toxin B associated conditions
US09/433,944 1999-11-04
PCT/CA2000/001312 WO2001032219A2 (en) 1999-11-04 2000-11-03 Treatment of c. difficile toxin b associated conditions

Publications (2)

Publication Number Publication Date
JP2003513051A true JP2003513051A (ja) 2003-04-08
JP2003513051A5 JP2003513051A5 (https=) 2007-12-06

Family

ID=23722193

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001534423A Pending JP2003513051A (ja) 1999-11-04 2000-11-03 Ｃ．ｄｉｆｆｉｃｉｌｅトキシンＢ関連性状態の処置

Country Status (6)

Country Link
US (1) US6358930B1 (https=)
EP (1) EP1250153A2 (https=)
JP (1) JP2003513051A (https=)
AU (1) AU1261601A (https=)
CA (1) CA2388187A1 (https=)
WO (1) WO2001032219A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008502606A (ja) * 2004-06-18 2008-01-31 バイオ−ケー・プラス・インターナショナル・インコーポレーテッド 乳酸菌及び下痢の予防におけるそれらの使用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7682631B2 (en) * 2003-10-01 2010-03-23 Clemson University Adhesin-specific nanoparticles and process for using same
AU2005295708A1 (en) * 2004-10-13 2006-04-27 Relypsa, Inc. Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle
US20060078534A1 (en) * 2004-10-13 2006-04-13 Dominique Charmot Toxin binding compositions
US20080107748A1 (en) * 2006-11-06 2008-05-08 Krishan Kumar Singal Microcapsules for removing and absorbing a chemical from a mixture
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
WO2011151620A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
ES2568455T3 (es) 2010-06-01 2016-04-29 Summit Therapeutics Plc Compuestos para el tratamiento de enfermedad asociada a Clostridium difficile

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635606A (en) * 1994-02-14 1997-06-03 Synsorb, Biotech Inc. Method of binding and removing toxin A
WO1998021218A1 (en) * 1996-11-08 1998-05-22 Synsorb Biotech, Inc. Solid support matrices containing a toxin binding oligosaccharide
JP2002516284A (ja) * 1998-05-28 2002-06-04 シンソーブ バイオテック， インコーポレイテッド Ｃ．ｄｉｆｆｉｃｉｌｅトキシンＢ関連性状態の処置

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1544908A (en) 1975-07-08 1979-04-25 Chembiomed Ltd Artificial oligosaccharide antigenic determinants
US4362720A (en) 1977-04-14 1982-12-07 Chembiomed Ltd. Synthesis of 2-amino-2-deoxyglycoses and 2-amino-2-deoxyglycosides from glycals
US5079353A (en) 1987-12-02 1992-01-07 Chembiomed, Ltd. Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
AU666128B2 (en) 1991-08-23 1996-02-01 Alberta Research Council Inc. Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients
US5811409A (en) 1995-06-05 1998-09-22 Synsorb Biotech, Inc. Treatment of cholera
US5637576A (en) 1995-06-05 1997-06-10 Synsorb Biotech, Inc. Treatment of traveller's diarrhea

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635606A (en) * 1994-02-14 1997-06-03 Synsorb, Biotech Inc. Method of binding and removing toxin A
WO1998021218A1 (en) * 1996-11-08 1998-05-22 Synsorb Biotech, Inc. Solid support matrices containing a toxin binding oligosaccharide
JP2002516284A (ja) * 1998-05-28 2002-06-04 シンソーブ バイオテック， インコーポレイテッド Ｃ．ｄｉｆｆｉｃｉｌｅトキシンＢ関連性状態の処置
JP2006213735A (ja) * 1998-05-28 2006-08-17 Synsorb Biotec Inc Ｃ．ｄｉｆｆｉｃｉｌｅトキシンＢ関連性状態の処置

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008502606A (ja) * 2004-06-18 2008-01-31 バイオ−ケー・プラス・インターナショナル・インコーポレーテッド 乳酸菌及び下痢の予防におけるそれらの使用

Also Published As

Publication number Publication date
WO2001032219A3 (en) 2002-04-04
CA2388187A1 (en) 2001-05-10
US6358930B1 (en) 2002-03-19
AU1261601A (en) 2001-05-14
WO2001032219A2 (en) 2001-05-10
EP1250153A2 (en) 2002-10-23

Similar Documents

Publication Publication Date Title
JP4122052B2 (ja) 抗生物質関連性下痢の処置
JP2002516284A (ja) Ｃ．ｄｉｆｆｉｃｉｌｅトキシンＢ関連性状態の処置
MXPA96003403A (en) Treatment of diarrhea associated with antibioti
JPH11506457A (ja) 旅行者の下痢の処置
JP2003513051A (ja) Ｃ．ｄｉｆｆｉｃｉｌｅトキシンＢ関連性状態の処置
Stoll et al. In vitro dissolution and in vivo absorption of nitrofurantoin from deoxycholic acid coprecipitates
JPH11506458A (ja) 旅行者の下痢の処置
JPH11506460A (ja) コレラの処置
JP2002503708A (ja) 抗生物質と毒素結合性オリゴ糖組成物を用いた細菌性赤痢の治療のための組成物と方法
WO2000056343A1 (en) Use of fucosylated sialylated n-acetyl lactosamine carbohydrate structures for inhibition of bacterial adherence
KR19990082194A (ko) 이. 콜라이 독소를 중화시키기 위한 올리고사카라이드의 용도
JPH11506459A (ja) コレラの処置
US5891860A (en) Treatment of traveller's diarrhea
NZ332531A (en) Oligosaccharide-peptide conjugate and use in treating cholera

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071019

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091217

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100720